News
02-24-2010, 11:34 PM
Harbor BioSciences, Inc. today announced that the company has received a notice of allowance from the United States Patent Office of patent claims covering the use of its lead product candidate Apoptone®. The patent claims cover the use of Apoptone to treat prostate cancer, breast cancer and benign prostatic hypertrophy. Apoptone (HE3235) is a novel synthetic steroid analog of a dihydrotestosterone metabolite and has been found to stimulate cell death (apoptosis) in animal models of prostate and breast cancers.
More... (http://www.news-medical.net/news/20100225/Harbor-BioSciences-to-receive-patent-for-Apoptone-in-treatment-of-prostate-cancer-breast-cancer-and-benign-prostatic-hypertrophy.aspx)
More... (http://www.news-medical.net/news/20100225/Harbor-BioSciences-to-receive-patent-for-Apoptone-in-treatment-of-prostate-cancer-breast-cancer-and-benign-prostatic-hypertrophy.aspx)